CPP-Cargo Conjugates: Peptide Delivery of siRNA, Drugs, Genes

Cell-Penetrating Peptides

~30 CPPs in clinical trials

Approximately 30 cell-penetrating peptides have entered clinical trials, though no CPP-drug conjugate has yet received FDA approval for cancer therapy.

Kim et al., Organic & Biomolecular Chemistry, 2026

Kim et al., Organic & Biomolecular Chemistry, 2026

The central problem of drug delivery is the cell membrane. Therapeutic molecules, particularly large ones like siRNA, proteins, and nucleic acids, cannot cross the lipid bilayer on their own. Cell-penetrating peptides (CPPs) solve this by ferrying cargo across the membrane through direct translocation or endocytosis. The challenge has never been getting CPPs into cells; it has been getting the right CPPs to deliver the right cargo to the right cells without destroying everything in between. For the foundational science on how CPPs work, see the pillar article on TAT Peptide: The HIV-Derived Delivery Vehicle for Cancer Therapy.

The conjugation problem

Attaching cargo to a CPP is not as simple as bolting a molecule onto a peptide. The conjugation strategy determines whether the cargo survives transit, whether the CPP retains its membrane-crossing ability, and whether the cargo is released in active form inside the cell. Three approaches dominate.

Covalent conjugation links the cargo directly to the CPP through chemical bonds. This includes disulfide bonds (cleavable in the reducing cytoplasmic environment), thioether bonds (stable), amide bonds, and click chemistry linkers. Behzadipour et al. (2019) developed a systematic bioinformatics workflow for selecting optimal CPPs for covalent conjugation to therapeutic proteins, finding that CPP selection, linker chemistry, and conjugation site all affect delivery efficiency.^[7]

Non-covalent complexation relies on electrostatic interactions between cationic CPPs and negatively charged cargo (particularly siRNA and DNA). The CPP wraps around the nucleic acid, forming nanocomplexes. Singh et al. (2018) reviewed CPP-siRNA complexation strategies and found that both covalent and non-covalent approaches achieved effective knockdown, though non-covalent complexes were simpler to prepare and showed higher loading capacity.^[8]

Nanoparticle incorporation embeds the CPP into a larger delivery vehicle, such as liposomes, micelles, or polymeric nanoparticles. Wang et al. (2018) demonstrated that lipid-modified CPPs could self-assemble into micelles for co-delivery of multiple therapeutic agents, achieving targeted drug accumulation while reducing systemic toxicity.^[9]

siRNA delivery: silencing genes through peptide carriers

Small interfering RNA (siRNA) is a potent gene-silencing tool, but its therapeutic potential has been limited by the difficulty of getting it into cells. siRNA is large (~13 kDa), negatively charged, and rapidly degraded in blood. CPPs address all three problems.

Furukawa et al. (2020) delivered siRNA into human hepatoma cells using amphipathic CPPs, demonstrating effective gene knockdown without significant cytotoxicity.^[10] The amphipathic design, with both hydrophobic and hydrophilic domains, is critical: it enables the CPP to interact with both the siRNA cargo and the lipid membrane simultaneously.

The linker between CPP and siRNA matters enormously. Wakamori et al. (2025) engineered a prodrug-type bifunctional CPP with a sterically refined redox-cleavable disulfide linker connecting the CPP to an integrin-targeting cRGD peptide. The disulfide bond remains intact in the oxidizing extracellular environment but cleaves in the reducing cytoplasm, releasing the siRNA payload precisely where it needs to act.^[2]

In a recent preclinical advance, Qasem et al. (2026) tested four different CPPs (R10, 10R-RGD, cRGD-10R, and iRGD-10R) for delivering siRNA to silence the LDHC gene in triple-negative breast cancer cells. Using a zebrafish xenograft model, they demonstrated significant tumor growth suppression, establishing that CPP-mediated siRNA delivery can produce measurable anti-tumor effects in vivo.^[11]

Drug conjugates: making chemotherapy more precise

Small-molecule drugs, particularly chemotherapeutics, kill cancer cells but also damage healthy tissue. Conjugating drugs to CPPs with tumor-targeting modifications can shift the therapeutic window.

Xiang et al. (2018) conjugated doxorubicin to dNP2, a human-derived CPP, and observed two-fold higher tumor inhibition compared to free doxorubicin in preclinical models, with reduced off-target toxicity.^[3] The human origin of dNP2 is relevant: CPPs derived from human proteins may be less immunogenic than viral-derived sequences like TAT.

Aguiar et al. (2019) explored a different application: coupling the antimalarial CPP TP10 to chloroquine and primaquine. The chloroquine-TP10 conjugates showed higher antiplasmodial activity than TP10 alone, demonstrating that CPP-drug conjugation can enhance efficacy for infectious disease, not just oncology.^[12] A caveat: these conjugates also produced strong hemolytic activity, illustrating the persistent challenge of membrane damage when cationic peptides interact with blood cells.

For a broader look at how peptides are being used as targeting vehicles for chemotherapy, see Peptide-Drug Conjugates: The Next Generation of Targeted Cancer Therapy.

Gene and protein delivery

Beyond small molecules and siRNA, CPPs can transport larger macromolecules including plasmid DNA and therapeutic proteins.

Allen et al. (2019) achieved cytosolic delivery of macromolecules in live human cells by combining the endosomal escape activities of a small molecule with CPP-mediated uptake, overcoming one of the persistent bottlenecks in intracellular delivery.^[13] Endosomal escape is the critical failure point: most CPP-cargo complexes enter cells through endocytosis and become trapped in endosomes, where they are degraded before reaching the cytoplasm.

Schneider et al. (2019) developed cleavable cyclic CPPs for targeted subcellular protein delivery. The cyclic structure increases protease resistance during transit, while the cleavable linker releases the protein payload at the intended intracellular destination.^[14]

For gene delivery specifically, the field is converging with the broader peptide gene therapy space, where CPPs serve as one of several non-viral delivery strategies competing with lipid nanoparticles and viral vectors.

Design evolution: from simple carriers to smart systems

The first generation of CPP-cargo conjugates were indiscriminate: they entered every cell they contacted, delivering cargo to healthy and diseased tissue alike. Three design strategies have emerged to address this.

Chimeric CPPs. Fadzen et al. (2019) demonstrated that chimeric peptides combining sequences from different parent CPPs produced synergistic improvement in antisense oligonucleotide delivery, exceeding what either parent peptide achieved alone.^[4] This combinatorial approach opens a design space that rational design alone cannot access.

Activatable CPPs. De Jong et al. (2020) reviewed 15 years of activatable CPP research, documenting multiple activation strategies including pH-responsive, enzyme-cleavable, and light-triggered systems.^[6] In these designs, the CPP's cell-penetrating ability is masked until it encounters a tumor-specific stimulus (low pH, overexpressed proteases, or externally applied light). This dramatically reduces uptake by healthy cells. The cluster article on tumor-activated cell-penetrating peptides covers this approach in detail.

AI-driven design. Kim et al. (2026) reviewed the latest design strategies and identified computational and AI-based design as the emerging frontier, enabling prediction of CPP properties, optimization of sequences for specific cargo types, and de novo generation of CPPs with targeted cell-type specificity.^[5] The combination of AI design with stimulus-responsive activation may ultimately solve the specificity problem.

The endosomal escape bottleneck

The single largest technical barrier in CPP-cargo delivery is endosomal trapping. When CPP-cargo complexes enter cells via endocytosis (the dominant uptake pathway for most cargoes), they are enclosed in endosomes. If the cargo cannot escape before the endosome matures into a lysosome, it is destroyed.

Multiple strategies target this bottleneck: fusogenic peptides that disrupt endosomal membranes at low pH, proton sponge effects from histidine-rich sequences, photochemical internalization using light to rupture endosomal membranes, and small-molecule co-delivery as demonstrated by Allen et al.^[13]

The efficiency of endosomal escape remains low, typically estimated at 1-5% of internalized cargo reaching the cytoplasm. This is why CPP-cargo systems require higher doses than would be necessary with perfect delivery, contributing to the toxicity challenges that have slowed clinical progress.

Clinical reality: promise and pipeline

Despite two decades of preclinical validation, CPP-cargo conjugates have moved slowly through clinical development. Approximately 30 CPPs have entered clinical trials, with PGN-EDO51 (a CPP-oligonucleotide conjugate for Duchenne muscular dystrophy) representing the most advanced clinical candidate. In preclinical and Phase I studies, it induced exon skipping and dystrophin production, demonstrating that CPP-mediated delivery of therapeutic oligonucleotides can work in human muscle tissue.

No CPP-drug conjugate has received FDA approval for cancer. The gap between preclinical promise and clinical translation reflects several unresolved problems:

• Proteolytic degradation: Natural L-amino acid peptides are rapidly cleaved by serum proteases, limiting circulation time. Strategies include D-amino acid substitution, backbone cyclization, and PEGylation, but each modification can reduce cell-penetrating efficiency.
• Non-specific uptake: The reticuloendothelial system (liver and spleen macrophages) captures nanoparticles and peptide complexes before they reach target tissue. This reduces the effective dose at the tumor site and increases hepatotoxicity risk.
• Immunogenicity: Foreign peptide sequences, particularly those derived from viral proteins like TAT, can trigger immune responses that reduce efficacy on repeat dosing. Human-derived CPPs like dNP2 may partially address this.
• Endosomal escape ceiling: Even with optimized escape strategies, only 1-5% of internalized cargo typically reaches the cytoplasm. This fundamental inefficiency means CPP-cargo systems require doses that approach toxicity thresholds.
• Manufacturing complexity: Covalent conjugation of CPP to cargo requires site-specific chemistry that must preserve both the CPP's membrane-crossing ability and the cargo's biological activity. Batch-to-batch consistency for clinical-grade production remains challenging.

The field appears to be converging on a consensus: first-generation CPPs (simple cationic sequences like TAT and polyarginine) will likely not reach approval as stand-alone delivery vehicles. The clinical candidates that advance will be second-generation designs combining activatable masking, targeting ligands, optimized linker chemistry, and potentially AI-designed sequences.

For cell-penetrating peptides in cancer drug delivery specifically, the tumor microenvironment offers activatable triggers (low pH, hypoxia, protease overexpression) that may eventually overcome the specificity barrier that has stalled broader clinical progress.

The Bottom Line

CPP-cargo conjugates can deliver siRNA, small-molecule drugs, proteins, and gene therapies past cell membranes using covalent conjugation, electrostatic complexation, or nanoparticle incorporation. Preclinical data shows meaningful improvements in delivery efficiency and therapeutic efficacy, including two-fold tumor inhibition with doxorubicin-CPP conjugates and effective gene silencing via CPP-siRNA nanocomplexes. The field has matured from indiscriminate delivery to smart systems using activatable, chimeric, and AI-designed CPPs. Clinical translation remains limited, with approximately 30 CPPs in trials but no FDA-approved cancer conjugate, largely due to endosomal escape inefficiency and in vivo stability challenges.

Frequently Asked Questions

What are CPP-cargo conjugates?

CPP-cargo conjugates are therapeutic systems that use cell-penetrating peptides to transport drug molecules, siRNA, proteins, or genetic material across cell membranes. The CPP acts as a molecular shuttle, carrying cargo that cannot enter cells on its own. Cargo is attached through covalent bonds (disulfide, thioether, amide), electrostatic complexation, or incorporation into nanoparticles. The goal is to improve intracellular delivery of therapies that would otherwise be blocked by the lipid bilayer.

How do cell-penetrating peptides deliver siRNA?

Cationic CPPs bind negatively charged siRNA through electrostatic interactions, forming nanocomplexes that enter cells via endocytosis or direct translocation. Once inside, the siRNA must escape endosomes to reach the cytoplasm where it can silence target genes. Recent advances include redox-cleavable disulfide linkers (Wakamori et al., 2025) that release siRNA specifically in the reducing cytoplasmic environment, and tumor-targeting modifications like RGD sequences that direct delivery to cancer cells.

Are any CPP drug conjugates FDA approved?

No CPP-drug conjugate has received FDA approval for cancer therapy as of 2026. Approximately 30 CPPs have entered clinical trials, with PGN-EDO51 (for Duchenne muscular dystrophy) being the most advanced. The gap between preclinical success and clinical approval reflects challenges in endosomal escape efficiency, in vivo peptide stability, non-specific tissue uptake, and immunogenicity of foreign peptide sequences.

What is the biggest challenge in CPP drug delivery?

Endosomal trapping is the primary bottleneck. Most CPP-cargo complexes enter cells through endocytosis and become enclosed in endosomes. If the cargo fails to escape before the endosome matures into a lysosome, it is destroyed. Typical endosomal escape efficiency is estimated at 1-5% of internalized cargo, requiring higher doses and contributing to off-target toxicity. Multiple strategies target this problem, including fusogenic peptides, proton sponge effects, and photochemical internalization.

What types of cargo can cell-penetrating peptides carry?

CPPs can transport four major cargo types: small-molecule drugs (chemotherapeutics, antimalarials), siRNA and antisense oligonucleotides for gene silencing, therapeutic proteins, and plasmid DNA for gene therapy. Each cargo type requires different conjugation strategies. Small molecules are typically covalently linked, siRNA uses electrostatic complexation or cleavable linkers, and proteins require site-specific conjugation to preserve function.

What is the difference between CPP drug conjugates and antibody drug conjugates?

CPP-drug conjugates use short peptides (typically 5-30 amino acids) to penetrate cell membranes and deliver cargo intracellularly. Antibody-drug conjugates (ADCs) use full antibodies to target specific cell-surface receptors, then rely on receptor-mediated endocytosis for internalization. CPPs are cheaper to produce and can cross membranes directly, but lack the targeting specificity of antibodies. The emerging strategy of combining CPPs with targeting peptides (like RGD sequences) aims to bridge this gap.